middle.news
Radiopharm Theranostics and Siemens Healthineers Partner to Supply RAD101 for Phase 3 Brain Metastases Trial
1:24pm on Tuesday 7th of April, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics and Siemens Healthineers Partner to Supply RAD101 for Phase 3 Brain Metastases Trial
1:24pm on Tuesday 7th of April, 2026 AEST
Key Points
RAD101 shows 90% concordance with MRI in Phase 2b interim analysis
Siemens Healthineers to supply Fluorine-18 labelled RAD101 for U.S. Phase 3 trial
FDA grants Fast Track Designation for RAD101 in brain metastases diagnosis
Partnership supports global multi-centre Phase 3 registrational trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE